Literature DB >> 18538101

Relapse of membranous glomerulopathy after kidney transplantation: sustained remittance induced by rituximab.

H Weclawiak1, D Ribes, C Guilbeau-Frugier, G Touchard, N Kamar, M Mehrenberger, A Modesto, L Rostaing.   

Abstract

Membranous glomerulopathy (MG) is a rare cause of chronic kidney disease. However, after kidney transplantation (KT), despite immunosuppression, it often relapses on the allograft. Herein, we report on a male kidney-transplant patient, aged 27 years, who developed overt nephrotic syndrome 11 months after KT. This was related to relapsing MG, as evidenced by the allograft biopsy, which, in addition, showed CD3 (+) and CD20 (+) interstitial lymphocyte infiltration. The patient was treated with rituximab: 375 mg/m2/week for 4 consecutive weeks, followed by one additional injection every 3 months for one year. Remission was observed before the third rituximab injection. After a follow-up of 42 months, the patient was still in remission, i.e., microalbuminuria of 107 mg/day.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538101     DOI: 10.5414/cnp69373

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation.

Authors:  Ben Sprangers; George Ian Lefkowitz; Scott D Cohen; Michael Barry Stokes; Antony Valeri; Gerald B Appel; Cheryl L Kunis
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

Review 2.  Rituximab therapy for membranous nephropathy: a systematic review.

Authors:  Andrew S Bomback; Vimal K Derebail; Julie G McGregor; Abhijit V Kshirsagar; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-11       Impact factor: 8.237

3.  Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab.

Authors:  Marco Ladino; David Roth
Journal:  NDT Plus       Date:  2009-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.